Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET-Reference-Cited by-同舟云学术

Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET

Published:2017-01 Issue: Volume:16 Page:153601211773666
ISSN:1536-0121
Container-title:Molecular Imaging
language:en
Short-container-title:Mol Imaging

Author:

Collier T. Lee¹²,Maresca Kevin P.³,Normandin Marc D.¹,Richardson Paul⁴,McCarthy Timothy J.³,Liang Steven H.¹,Waterhouse Rikki N.³⁵,Vasdev Neil¹

Affiliation:

1. Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital (MGH) & Department of Radiology, Harvard Medical School, Boston, MA, USA

2. Advion, Inc, Ithaca, NY, USA

3. Clinical and Translational Imaging, Worldwide Research and Development, Pfizer Inc, Cambridge, MA, USA

4. Medicinal Sciences, Pfizer Inc, La Jolla, CA, USA

5. Waterhouse Imaging and Biomarker Consultants, Chester, NH, USA

Publisher

SAGE Publications

Subject

Condensed Matter Physics,Radiology Nuclear Medicine and imaging,Biomedical Engineering,Molecular Medicine,Biotechnology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1536012117736669

Reference10 articles.

1. Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib

2. Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations

3. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival

4. Spirocyclic hypervalent iodine(III)-mediated radiofluorination of non-activated and hindered aromatics

5. Mechanistic studies and radiofluorination of structurally diverse pharmaceuticals with spirocyclic iodonium(iii) ylides

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Spotlight on the treatment of non‐small cell lung cancer with rare genetic alterations and brain metastasis: Current status and future perspectives;International Journal of Cancer;2024-07-03

2. Tyrosine kinase inhibitors in cancers: Treatment optimization – Part I;Critical Reviews in Oncology/Hematology;2024-07

3. Advances of clinically approved small-molecule drugs for the treatment of non-small cell lung cancer;European Journal of Medicinal Chemistry;2023-12

4. Synthesis and clinical application of small-molecule inhibitors and PROTACs of anaplastic lymphoma kinase;Bioorganic Chemistry;2023-11

5. Chemistry and Pharmacology of Fluorinated Drugs Approved by the FDA (2016–2022);Pharmaceuticals;2023-08-15